| __timestamp | Blueprint Medicines Corporation | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 1213000 |
| Thursday, January 1, 2015 | 14456000 | 3425000 |
| Friday, January 1, 2016 | 19218000 | 6311000 |
| Sunday, January 1, 2017 | 27986000 | 9518000 |
| Monday, January 1, 2018 | 47928000 | 28080000 |
| Tuesday, January 1, 2019 | 96388000 | 36550000 |
| Wednesday, January 1, 2020 | 157743000 | 46125000 |
| Friday, January 1, 2021 | 195293000 | 68486000 |
| Saturday, January 1, 2022 | 237374000 | 92032000 |
| Sunday, January 1, 2023 | 295141000 | 117532000 |
| Monday, January 1, 2024 | 359272000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Blueprint Medicines Corporation and Rhythm Pharmaceuticals, Inc. have been navigating this landscape since 2014. Over the past decade, Blueprint Medicines has seen its SG&A expenses grow by approximately 3,600%, reaching nearly $295 million by 2023. In contrast, Rhythm Pharmaceuticals has managed a more modest increase of around 9,600%, with expenses peaking at about $118 million in the same year.
Blueprint's aggressive expansion strategy is evident in its rising costs, reflecting its commitment to growth and market penetration. Meanwhile, Rhythm's more conservative approach suggests a focus on sustainable scaling. As these companies continue to evolve, their SG&A strategies will be pivotal in determining their long-term success in the biotech arena.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.